SCHEMBL2059340

SCHEMBL2059340

CC(=O)OC[C@@]1(C2CC[C@@]3(C)C(CC[C@H]4[C@@H]5CC[C@H]([C@H](C)CCCC(C)C)[C@@]5(C)CC[C@@H]43)C2)O[C@H](O)[C@@H](N2C(=O)c3ccccc3C2=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ EBP Q15125 1/20 0.48
▸ DHCR7 Q9UBM7 1/20 0.48
▸ CDC25A P30304 5/20 0.47
▸ POLA1 P09884 1/20 0.44
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ USP2 O75604 2/20 0.42
▸ VDR P11473 1/20 0.42
▸ INPP5D Q92835 1/20 0.42
▸ HPSE Q9Y251 4/20 0.40
▸ CDC25B P30305 1/20 0.40
▸ NPC1L1 Q9UHC9 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ CD4 P01730 2/20 0.40
▸ FNTA P49354 1/20 0.39
▸ FNTB P49356 1/20 0.39
▸ CCR1 P32246 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2059335 1.00 EBP (0.48) EBPDHCR7CDC25APOLA1CYP2D6
SCHEMBL2058823 0.83 CDC25A (0.49) CDC25APOLA1CYP2D6CYP2C19USP2
SCHEMBL2058819 0.83 CDC25A (0.49) CDC25APOLA1CYP2D6CYP2C19USP2
SCHEMBL2059338 0.79 HPSE (0.54) CDC25AHPSE
SCHEMBL2224267 0.75 CYP2D6 (0.60) EBPDHCR7CDC25APOLA1CYP2D6
SCHEMBL24403430 0.70 VDR (0.79) CDC25APOLA1CYP2D6CYP2C19USP2
SCHEMBL11371121 0.70 VDR (0.79) CDC25APOLA1CYP2D6CYP2C19USP2
SCHEMBL12205280 0.70 VDR (0.79) CDC25APOLA1CYP2D6CYP2C19USP2
SCHEMBL15372968 0.70 VDR (0.79) CDC25APOLA1CYP2D6CYP2C19USP2
SCHEMBL4739362 0.70 VDR (0.79) CDC25APOLA1CYP2D6CYP2C19USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1921086-B1 ANTITUMOR AGENT OTSUKA PHARMA CO LTD (JP) 2014-04-16 — — EP disclosed
US-7968116-B2 Antitumor agent OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-06-28 — — US disclosed
US-20100292176-A1 ANTITUMOR AGENT OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-11-18 — — US disclosed
EP-1921086-A1 ANTITUMOR AGENT Otsuka Pharmaceutical Co., Ltd. (JP) 2008-05-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292176-A1 ANTITUMOR AGENT CYP46A1, CETP, GYS2 EBP 162/4885DHCR7 4/4885CDC25A 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback